BURLINGTON, Mass.– The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the U.S. and Canada business of Merck KGaA, Darmstadt, Germany in the December 17 announcement. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development. Terms of the deal were not disclosed.
“The use of organoids offers tremendous potential to improve the drug discovery process,” said Jean-Charles Wirth, Head of Science and Lab Solutions for the Life Science Business of Merck KGaA, Darmstadt, Germany. “HUB’s advanced technology, combined with our innovations in 3D cell culture and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of organoids to understand the impact of drug response earlier in the development process.”
HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing the Life Science business of Merck KGaA, Darmstadt, Germany’s offering of cell culture tools to academia, biotech, and pharma customers. The team of approximately 70 employees is celebrating the acquisition together at the HUB campus in Utrecht, Netherlands.
